Arcellx Shares Rise Premarket on Expanded Gilead Collaboration
15 Novembro 2023 - 10:30AM
Dow Jones News
By Colin Kellaher
Shares of Arcellx jumped more than 10% in premarket trading
Wednesday after the clinical-stage biotechnology company inked an
extension of its collaboration with Gilead Sciences that includes a
$200 million equity investment at a rich premium.
Gilead, which late last year invested $100 million for a nearly
7.2% stake in Arcellx, is buying an additional 3.24 million share
at $61.68 each, 30% above Tuesday's closing price of $47.47 and
nearly triple Arcellx's closing price of $21.68 on Dec. 8, 2022,
the day before the companies unveiled their collaboration.
The new investment will raise Gilead's stake in Arcellx to
around 13%, making it the Gaithersburg, Md., company's largest
shareholder, according to FactSet data.
Arcellx shares were recently up 12% to $53.26 in premarket
trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 08:15 ET (13:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
